Role of the fusion peptide and membrane-proximal domain in HIV-1 envelope glycoprotein-mediated membrane fusion.

Biochemistry

Laboratory of Experimental and Computational Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, Maryland 21702-1201, USA.

Published: December 2003

The N-terminal fusion peptide and the interfacial sequence preceding the transmembrane anchor of HIV-1 gp41 are required for viral fusion. Studies with synthetic peptides indicated that these regions function by destabilizing membranes, which is regarded as a crucial step in the membrane fusion reaction. However, it is not clear whether membrane destabilization is induced by these sequences in the intact gp41. We address this question by examining fusion and destabilization of membranes expressing HIV-1(IIIB) wild-type Env and two mutant Envs. (1) A Glu residue at position 2 of the gp41 fusion peptide is substituted for Val (V2E) to produce one mutant. (2) Residues 665-682 in the membrane-proximal domain are deleted to form the other. The process of membrane destabilization was monitored by the influx of Sytox, an impermeant fluorescent dye, into the Env-expressing cells following the interaction with CD4-CXCR4 complexes, and fusion was monitored by observing dye transfer between Env-expressing cells and appropriate target cells. We also monitored the conformational changes in the Envs following their interactions with CD4 and CXCR4 by immunofluorescence using an anti-gp41 mAb that reacts with the six-helix bundle. In contrast to the wild type, both Env mutants did not mediate cell fusion. The V2E Env did not mediate membrane destabilization. However, the Env with an unmodified fusion peptide but with a deletion of residues 665-682 in the membrane-proximal domain did mediate membrane destabilization. The wild type and both mutant Envs undergo conformational changes detected by the anti-gp41 six-helix bundle mAbs. Our results suggest that in intact HIV-1 Env the membrane-proximal domain is not required for membrane perturbations, but rather enables the bending of gp41 that is required for viral and target membranes to come together. Moreover, the observation that the Delta665-683 Env self-inserts its fusion peptide but does not cause fusion suggests that self-insertion of the fusion peptide is not sufficient for HIV-1 Env-mediated fusion.

Download full-text PDF

Source
http://dx.doi.org/10.1021/bi035154gDOI Listing

Publication Analysis

Top Keywords

fusion peptide
24
membrane-proximal domain
16
membrane destabilization
16
fusion
13
membrane fusion
8
gp41 required
8
required viral
8
mutant envs
8
residues 665-682
8
665-682 membrane-proximal
8

Similar Publications

Purpose: To evaluate changes in the retinal microvasculature using widefield swept-source optical coherence tomography angiography (SS-OCTA) following three anti-vascular endothelial growth factor (anti-VEGF) loading injections for diabetic macular edema (DME).

Methods: Thirty-four treatment-naïve patients with DME received an initial three loading injections, followed by injections on an as-needed basis. Macular ischemia was evaluated based on the foveal avascular zone (FAZ) area, perfusion density, and vessel density on a 3 × 3-mm SS-OCTA image.

View Article and Find Full Text PDF

Background: This study introduces the Automated High-purity Exosome isolation-based AD diagnostics system (AHEADx). By analyzing and understanding the molecular cargo (proteins and miRNAs) carried by circulating exosomes, researchers found brain-derived exosome (BDE) levels of P-S396-tau, P-T181-tau, and Aβ1-42 are elevated up to 10 years prior to clinical symptoms. Currently, there is no available technology capable of simultaneously isolating and screening exosomal biomarkers for efficient and personalized precision medicine giving early AD diagnosis.

View Article and Find Full Text PDF

Biomarkers.

Alzheimers Dement

December 2024

Instituto de Salud Carlos III, Madrid, Madrid, Spain.

Background: Alzheimer's disease (AD) is the most common neurodegenerative disease worldwide and the leading cause of dementia in the elderly. New approaches to study AD are still needed to identify and validate blood-based diagnostic biomarkers that could be useful for its early diagnosis. Circulating autoantibodies (AAbs) and their target proteins (autoantigens) are promising candidate biomarkers to aid in AD early diagnosis.

View Article and Find Full Text PDF

Biomarkers.

Alzheimers Dement

December 2024

Department of Psychiatry, McGill University, Montréal, QC, Canada.

Background: Synapse loss in Alzheimer's disease (AD) is correlates closely with cognitive impairment. Recent evidence suggests that synapse loss is promoted by amyloid-beta, leading in turn to the spread of tau pathology. We sought to assess: 1) the association in positron emission tomography (PET) between several cerebrospinal fluid (CSF) synaptic biomarkers and amyloid and tau burden, as well as their annual change; and 2) the potential clinical utility of these synaptic biomarkers in preclinical AD.

View Article and Find Full Text PDF

Biomarkers.

Alzheimers Dement

December 2024

Radiology Department, Duke University Medical Center, Durham, NC, USA.

Background: While we do not yet have the means to detect early Alzheimer's disease (AD), studying subjects at risk conferred by the presence of the APOE4 allele, can provide useful information before clinical onset. We show that using symmetric bilinear regression with L1 penalty (SBL) of individual (DTI, fMRI) and fused connectomes, we can identify vulnerable regions changing in association with hallmark AD biomarkers measured in cerebrospinal fluid: amyloid beta Aβ42/40, phosphorylated tau (PTAU), and neurofibrillary light (NfL) as a proxy for neurodegeneration.

Methods: We use structural connectomes derived from diffusion-weighted MRI (DTI) and functional connectomes (fMRI) from 57 subjects, 45 normal controls and 12 cognitively impaired to predict CSF Aβ42/40, PTAU, and NfL to reflect neurodegeneration.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!